Justin Kim
Stock Analyst at Oppenheimer
(1.50)
# 3,208
Out of 4,711 analysts
36
Total ratings
39.29%
Success rate
-9.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $33.21 | +20.45% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $19.57 | +114.61% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $48.87 | +116.90% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $28.33 | +207.15% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $42.60 | -38.97% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $4.88 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $2.28 | +645.61% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $9.03 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $7.57 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $35.63 | +65.59% | 1 | Jul 18, 2022 |
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $33.21
Upside: +20.45%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $19.57
Upside: +114.61%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $48.87
Upside: +116.90%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $28.33
Upside: +207.15%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $42.60
Upside: -38.97%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.88
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $2.28
Upside: +645.61%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.03
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.57
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $35.63
Upside: +65.59%